Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07773727 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07773727 · ClinicalTrials.gov record · last posted 2026-08-19

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

Study acronym: Verdant
StatusNot Yet Recruiting
PhasePhase 2
Sponsorargenx
Started2026-10-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN. While in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise. The study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.
Trial Details
NCT Number NCT07773727
Lead Sponsor argenx
Conditions Immunoglobulin A Nephropathy (IgAN)
Enrollment 120 participants
Start Date 2026-10-15
Primary Completion 2029-10-29 (estimated)
Study Completion 2030-02-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-19